Join
Live feed
·
INSIDERFilingvia Quantisnow
CRISPR Therapeutics AG logo

Chief Executive Officer Kulkarni Samarth converted options into 8,334 shares and sold $282,517 worth of shares (4,242 units at $66.60), increasing direct ownership by 2% to 205,096 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRSP (CRISPR Therapeutics AG) and more on Quantisnow.